We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 00:26:37 |
By Colin Kellaher
Werewolf Therapeutics Inc. on Wednesday said it formed a collaboration and supply agreement with Merck & Co. to study Werewolf's WTX-124 product candidate in combination with Merck's blockbuster cancer drug Keytruda.
Werewolf, a Cambridge, Mass., biopharmaceutical company, said it plans to conduct a Phase 1 clinical trial to evaluate the safety and preliminary efficacy of WTX-124 as a monotherapy and in combination with Keytruda in patients with solid tumors.
Werewolf said it plans to file for U.S. Food and Drug Administration approval of the trial in the first half of 2022.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 18, 2021 08:37 ET (12:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions